The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Open accessAbstract
BACKGROUND: Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. METHODS: We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. RESULTS: An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G→A and IVS3+1G→T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1×10(-20)), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P=8×10(-10)). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P=4×10(-6)). CONCLUSIONS: Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, loss-of-function mutations in APOC3, which encodes apolipoprotein C-III, result in significantly lower plasma TG levels and confer a 40–50% lower risk of ischemic cardiovascular events [25].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with loss-of-function mutations in APOC-III exhibit significantly reduced levels of triglycerides and remnant cholesterol, along with a nearly 40% reduction in ASCVD risk [32, 33].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with genetic loss-of-function mutations in the APOC3 gene exhibit markedly lower TG levels and reduced incidence of CAD, highlighting apoC-III as a compelling therapeutic target for HTG and associated complications [25, 29, 43].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [120]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [64]
In the citing paper
“ApoCIII has been identified as a potentially important new risk factor. 104-106”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Robust relationship inference in genome-wide association studies
Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq559 · Cited by 3,541
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Taylor HA, 2005, Ethn Dis, 15, S4
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Pediatric dyslipidemias: lipoprotein metabolism disorders in children
Ballout, R. A., & Remaley, A. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817962-8.00002-0 · Cited by 3
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
J-shaped association between circulating apoC-III and cardiovascular mortality
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G. E., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa169 · Cited by 2
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 2
Endogenous and exogenous factors affecting lipoprotein lipase activity
Larsson, M. (2014) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Slippery Slope of Triglycerides
Watson, K. E., & Wiesner, P. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002675 · Cited by 2
What are the prospects of apolipoprotein profiling for cardiovascular disease?
Baig, F., & Mayr, M. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1352472 · Cited by 2
Association Analysis and Meta-Analysis of Multi-allelic Variants for Large Scale Sequence DataPreprint
Zhan, X., Chen, S., Jiang, Y., Liu, M., Iacono, W. G., Hewitt, J. K., Hokanson, J. E., Krauter, K. S., Laakso, M., Li, K. W., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/197913 · Cited by 2
Jiang, B., Chen, S., Jiang, Y., Liu, M., Iacono, W. G., Hewitt, J. K., Hokanson, J. E., Krauter, K. S., Laakso, M., Li, K. W., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/222695 · Cited by 2
Lipid metabolism: spotlight on modulators of lipoprotein lipase activity
Arndt, L., & Burkhardt, R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000501 · Cited by 2
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Yamanaka, T., Ishihara, T., Miyata, K., Ichinohe, Y., & Fukatsu, T. (2023) · Cureus · doi:10.7759/cureus.39170 · Cited by 1
Genetic aspects of decreased low-density lipoprotein cholesterol values
Meshkov, A. N., Ershova, A. I., Kiseleva, A. V., Mikhailina, V. I., Smetnev, S. A., Soplenkova, A. G., Kutsenko, V. A., Сотникова, Е. А., Vyatkin, Y. V., Zharikova, A. A., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3846 · Cited by 1
Malick, W. A., Rosenson, R. S., Naidu, I., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_5 · Cited by 1
Hypertriglyceridemia (> 150 mg/dL) as a marker of cardiovascular risk
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500822 · Cited by 1
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
Nordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 2
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
Zhu, Y., Yuan, R., Lu, Z., Zhang, Y., Kang, Z., Feng, X., Zhao, G., Sun, J., Guo, J., Yu, T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102653 · Cited by 1
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 2
Zhang, W., Yoshiji, S., SLADEK, R. M., Dupuis, J., & Lu, T. (2026) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzag087 · Cited by 2
Genetic Epidemiology of Atherosclerotic Vascular Disease
O’Donnell, C. J., & Fu, Y. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_47 · Cited by 1
Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say
Kei, A. A., & Elisaf, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12762 · Cited by 1
Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents
Gotto, A. M., & Pownall, H. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_28 · Cited by 1
JCL roundtable: Lessons from genetic variants altering lipoprotein metabolism
Brown, W. V., Ference, B. A., & Kathiresan, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.002 · Cited by 1
The Role of Omega-3 Fatty Acids in Dyslipidemias
Brandt, E. J., & Davidson, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_5 · Cited by 1
The Advent of High-Throughput Sequencing Studies of Chronic Obstructive Pulmonary Disease
Ortega, V. E., & Celedon, J. C. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0074ed · Cited by 1
Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases
Swerdlow, D. I., Michail, M., & Zacharias, K. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00008-2 · Cited by 2
The State of Cardiovascular Genomics: Abundant Data, Limited Information
Aslibekyan, S. W., & Ruiz-Narváez, E. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.03.012 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Stryukova, E. V., Maksimov, V. N., Ragino, Y. I., Polonskaya, Y. V., Murashov, I. S., Волков, А. М., Кургузов, А. В., Chernjavskii, A. M., & Kashtanova, E. V. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100847 · Cited by 1
Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins
Kachkovsky, M. A., Vvedenskaya, I. P., Vvedensky, V. Y., Supilnikov, A. A., Ponomareva, J. V., & Milyakova, M. N. (2020) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2020.4.11 · Cited by 1
Wiggins, B. S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001132 · Cited by 1
Al-Lamee, R. K., Aubinière-Robb, L., & Berry, C. (2022) · Heart · doi:10.1136/heartjnl-2021-320150 · Cited by 1
Personalized Therapy of Cardiovascular Disorders
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_13 · Cited by 1
A copula-based set-variant association test for bivariate continuous, binary or mixed phenotypes
St‐Pierre, J., & Oualkacha, K. (2022) · The International Journal of Biostatistics · doi:10.1515/ijb-2022-0010 · Cited by 2
Precision Medicine in Cardiovascular Disease Practice
Sheikhy, A., Fallahzadeh, A., Meybodi, H. R. A., & Hosseini, K. (2022) · Springer eBooks · doi:10.1007/978-981-19-5082-7_4 · Cited by 1
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Medicinal Herbs as an Alternative Treatment in the Management of Hyperlipidemia
Sen, A. K., Balaraman, R., Sen, D. B., Dash, D. K., & Maheshwari, R. A. (2023) · Journal of Natural Remedies · doi:10.18311/jnr/2023/32174 · Cited by 2
Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment
Roy, T., Ray, A. G., & Bandyopadhyay, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00081-5 · Cited by 1
Treating Cardiovascular Disorders with Personalized Medicine
Garg, I., Kumar, H., Verma, M., Chauhan, I., & Panwar, V. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x361429250215190129 · Cited by 2
Basics in Lipoprotein Metabolism
Yassine, H. N., Tappin, K., & Sethi, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-11161-2_1 · Cited by 1
Obesity research: Status quo and future outlooks
Gammal, A. T. E. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i3.119 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Genetics and Valve Calcification ∗
Brown, W. V. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.048 · Cited by 1
Genetics and Genomics of Coronary Artery Disease
Yamada, Y., & Yasukochi, Y. (2018) · Springer eBooks · doi:10.1007/978-3-319-66114-8_22 · Cited by 1
Genetics and Genomics of Atherosclerotic Cardiovascular Disease
Musunuru, K., Qasim, A., & Reilly, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00007-0 · Cited by 2
Prospective Advances in Non-coding RNAs Investigation
Jan, M. I., Ali, T., Ishtiaq, A., Mushtaq, I., & Murtaza, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_24 · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 2
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
Libby, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00005-0 · Cited by 1
What's all this fuss about the gene?
Olby, R. (2014) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2014.11.001 · Cited by 1
Mendelian Randomisation: A MinireviewPreprint
Wells, D. (2017) · doi:10.22541/au.149652750.03402000 · Cited by 1
Lotta, L. A., Dong, L., Li, C., Patel, S., Stewart, I. D., Lim, K., Day, F. R., Wheeler, E., Glastonbury, C. A., de Streek, M. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372128 · Cited by 2
Role of Rare and Low Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid LevelsPreprint
Wang, Z., Chen, H., Bartz, T. M., Bielak, L. F., Chasman, D. I., Feitosa, M. F., Franceschini, N., Guo, X., Lim, E., Noordam, R., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/561225 · Cited by 1
The Genetics of Coronary Heart Disease
Erdmann, J., & Venegas, M. L. M. (2019) · Cardiac and vascular biology · doi:10.1007/978-3-030-27371-2_4 · Cited by 1
Vitali, C., Stankov, S. G., Khetarpal, S. A., Millar, J. S., Mayne, L. C., Englander, S. W., Hand, N. J., Lund‐Katz, S., Phillips, M. C., & Rader, D. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.183178 · Cited by 1
Rodríguez, M. M., Rehues, P., Iranzo, V., Mora, J. D., Balsells, C., Guardiola, M., & Ribalta, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.15.298802 · Cited by 1
Leveraging a founder population to identify novel rare-population genetic determinants of lipidomePreprint
Montasser, M. E., Aslibekyan, S. W., Srinivasasainagendra, V., Tiwari, H. K., Patki, A., Bagheri, M., Kind, T., Barupal, D. K., Fan, S., Perry, J. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.21.445208 · Cited by 1
Stankov, S. G., Vitali, C., Park, J., Nguyen, D., Mayne, L. C., Englander, S. W., Levin, M. G., Vujković, M., Hand, N. J., Phillips, M. C., et al. (2023) · medRxiv · doi:10.1101/2023.02.21.23286268 · Cited by 1
Apolipoprotein C3 and cardiovascular risk: new insights from the ODYSSEY outcomes trial
Catapano, A. L., Pirillo, A., & Tokgözoğlu, L. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf202 · Cited by 1
Bench to all Bedsides in Genomics and Precision Medicine
Tcheandjieu, C., Robinson, C., & Natarajan, P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039202 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.039
Genetic Epidemiology of Complex Traits
Rana, B. K., Vivo, I. D., & Schork, N. J. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0005412.pub3
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Lipid-modifying Therapy: The Clinician’s Perspective
Thompson, P. L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.10.002
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Lander, E. S. (2014) · DSpace@MIT (Massachusetts Institute of Technology)
Detection of Genes Influencing Chronic and Mendelian Disease via Loss-Of-Function Variation
Li, A. H. (2015) · Digital Commons-TMC (Texas Medical Center)
Apolipoprotein C-III's role in cardiovascular diseases, a short review
Emilian, O. G. (2014) · ScienceOpen Research · doi:10.14293/s2199-1006.1.sor-med.afafp0.v1
Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination
Patel, S. B. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.1506
Amati, F., & Widmann, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000118
Leopold, J. A. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000367
GWAS as a Driver of Gene Discovery in Cardiometabolic
Kumar, V., Fu, J., Wijmenga, C., & Hofker, M. H. (2015)
Genomic Medicine and Ethnic Differences in Cardiovascular Disease Risk
Wood, A. C., & Rich, S. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799961-6.00009-3
Enhancing genetic discoveries with population-specific reference panels
Sanna, S. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Gordon, A. (2015) · ResearchWorks at the University of Washington (University of Washington)
Coronary Artery Disease and Myocardial Infarction
Assimes, T. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800685-6.00008-4
Situación actual en genómica cardiovascular: muchos datos, poca información
Aslibekyan, S. W., & Ruiz-Narváez, E. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.03.014
Identification of genetic modifiers in LRRK2 parkinsonism
Trinh, J. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0340339
West, G. (2017) · OpenCommons - UConn (University of Connecticut)
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019?
Park, J. E., & Miller, M. J. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0603-3
Kathiresan, S. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.011
Dissecting the role of apolipoprotein CIII in diabetic wound healing
Cho, M. M. W. (2019) · doi:10.32657/10220/48515
Farukhi, Z. M., & Mora, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.916
Ozaki, K., & Tanaka, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-8177-5_2
Genetic analysis of DNA methylation in dyslipidemia: a case-control studyPreprint
Ma, Y.-T., Liu, S., Li, Y., Wei, X., Adi, D., Wang, Y., Han, M., Liu, F., Chen, B., Li, X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-113737/v1
Choosing a genome editing strategy and target site
Musunuru, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823484-6.00011-6
Björnson, E. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
New Agents for Treatment of Dyslipidemia
Simha, V. (2021) · Clinical Dilemmas in Diabetes · doi:10.1002/9781119603207.ch17
Genetics of (Premature) Coronary Artery Disease
Erdmann, J., & Schunkert, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-44203-7_22
Metadata
- Authors
- The TG and HDL Working Group of the Exome Sequencing Project, N. H.
- Corresponding author
- The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4180269
- OpenAlex
- W2170009139
- Semantic Scholar
- b3c2b9d4976782980ff38a64e223209866004dcc
- Cited by
- 1,071
- References
- 66
- Citations by year
- 2026: 52 · 2025: 73 · 2024: 48 · 2023: 56 · 2022: 75 · 2021: 93 · 2020: 110 · 2019: 90 · 2018: 81 · 2017: 113 · 2016: 132 · 2015: 107 · 2014: 41
- FWCI
- 89.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- U.S. Department of Agriculture
- Massachusetts General Hospital (R01HL107816)
- University of Wisconsin-Milwaukee
- George Washington University
- University of Washington
- Donovan Family Foundation
- University of Ottawa
- Norges Teknisk-Naturvitenskapelige Universitet
- Queen Mary University of London
- Wellcome Trust
- Deutsches Zentrum für Herz-Kreislaufforschung
- Università degli Studi di Milano
- University of Texas Health Science Center at Houston
- Broad Institute
- Russell and Diana Hawkins Family Foundation
- National Institute for Health and Care Research (NF-SI-0611-10170)
- British Heart Foundation
- University of Leicester
- University of Oxford
- University of Leeds
- Fondation Leducq (T32HL007208)
- Lunds Universitet
- Hjärt-Lungfonden
- King Abdulaziz University
- Universität zu Lübeck
- Umeå Universitet
- Technische Universität München
- Università degli Studi di Verona
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339, NNF14OC0011049)
- Regione Emilia-Romagna
- National Institutes of Health (1rc2hl103010-01)
- School of Medicine, Stanford University
- University of North Carolina at Chapel Hill
- Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai
- Canadian Institutes of Health Research
- Medical Research Council
- Barts and The London School of Medicine and Dentistry
- Helmholtz Zentrum München
- National Institute on Aging (P30AG010129, U01AG049505)
- National Heart, Lung, and Blood Institute (HL 102923, RC2HL102925, HL-102924, K08HL114642, RC2HL102926, RC2HL102923, RC2HL-103010, HL 103010, RC2HL102924, R01HL107816, T32HL007208, R01HL109946)
- National Cancer Institute (R01CA082659)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein C-III, loss-of-function mutations, plasma triglycerides, coronary artery disease, rare variants, splice site mutation, nonsense mutation, missense mutations, genetic risk, European ancestry, African ancestry
- MeSH terms
- Coronary Disease, Genotype, Heterozygote, Humans, Liver, Mutation, Risk Factors, Triglycerides, Sequence Analysis, DNA, Black People, White People, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
